Litigation Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)

AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)

Docket	1:23-cv-01332	Date Filed	2023-11-20
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	HETERO LABS LIMITED
Patents	10,519,164; 8,962,629; 9,951,080; 9,963,459; RE47,221
Attorneys	Jack B. Blumenfeld
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for AbbVie Inc. v. Hetero USA, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-11-20	1	Complaint	393 Patent”); 10,519,164 (“the ’164 Patent”); 10,730,883 (“the ’883 Patent”); 10,981,924 (“the ’924 Patent… United States Patent Nos. RE47,221 (“the RE’221 Patent”); 8,962,629 (“the ’629 Patent”); 9,951,080 (… (“the ’080 Patent”); 10,981,923 (“the ’923 Patent”); 11,186,584 (“the ’584 Patent”); 11,661,425 (“the…the ’425 Patent”); 11,680,069 (“the ’069 Patent”); 11,718,627 (“the ’627 Patent”); 11,198,697 (“the ’… ’697 Patent”); 9,963,459 (“the ’459 Patent”); 10,344,036 (“the ’036 Patent”); 10,202,393 (“the ’393	External link to document

AbbVie v. Hetero USA, Inc. (1:23-cv-01332): Litigation Summary, Patent Scope, and Commercial Risk Analysis

Last updated: July 16, 2026

What claims and patents are at issue in AbbVie Inc. v. Hetero USA, Inc. (1:23-cv-01332)?

Executive summary: The docket 1:23-cv-01332 is a patent infringement case filed by AbbVie Inc. against Hetero USA, Inc. The litigation centers on an FDA generic/biosimilar entry product covered by AbbVie’s asserted intellectual property. The case posture, asserted patent set, and claim construction schedule determine launch timing exposure, settlement leverage, and the likelihood of a consent judgment or near-term noninfringement findings.

Court and case characteristics

• Case number: 1:23-cv-01332
• Parties: AbbVie Inc. (plaintiff) vs. Hetero USA, Inc. (defendant)
• Nature of suit: Patent infringement (generic/bio-application related, per standard Hatch-Waxman or related infringement framework in AbbVie/Hetero matters)
• Venue: Federal district court in the United States (case ID indicates federal litigation in the Northern District of Illinois or another federal district depending on filing caption; the docket number alone does not identify jurisdiction for all queries)

What to focus on in claim scope In AbbVie vs. generic manufacturers, the infringement theory typically maps to one or more of the following patent categories:

• Product formulation/composition patents (active ingredient dispersion, salt form, excipients, or stability-directed compositions)
• Method-of-use patents (approved indication dosing regimen, monitoring, or administration technique)
• Manufacturing method patents (process steps affecting impurity profile or bioavailability)
• Drug-device or delivery system patents (less common for oral small molecules, more common when AbbVie products use specialized delivery)

Featured snippet answer: The litigation targets patent-protected aspects of AbbVie’s product tied to an ANDA-style or closely related regulatory entry by Hetero; the key infringement hinge is whether Hetero’s proposed product and manufacturing method fall within AbbVie’s asserted claims.

Which asserted patent categories usually drive AbbVie v. Hetero disputes?

• Composition claims: Typically carry strong claim construction impact because generic products may change excipients, particle size, or manufacturing conditions.
• Method-of-use claims: Often narrow through “treatment/administration” limitation parsing; if Hetero’s labeling design-around is credible, method claims can become vulnerable.
• Process claims: Require technical proof and often reduce ease of early resolution unless the record includes admissions about manufacturing steps.

What is the litigation timeline for AbbVie v. Hetero (1:23-cv-01332)?

Executive summary: The case timeline drives whether the parties pursue early dispositive motions (noninfringement/invalidity) versus negotiating a settlement conditioned on FDA exclusivity and triggering date controls.

Timeline signals typically used in these cases

• Complaint filing date (2023): initiates infringement claims and starts the schedule for initial disclosures and early claim construction.
• Answer/defenses: indicates validity and noninfringement grounds, including potential Section 112, obviousness, and indefiniteness defenses.
• Markman/claim construction: determines meaning of key limitations and can quickly narrow scope.
• Scheduling order: sets expert discovery, Daubert motions, summary judgment deadlines, and trial date.
• Stay events: may occur if related PTO proceedings (IPR/Ex Parte Reexamination) are filed or if there is a parallel appeal.
• Preliminary injunction motions (rare, but high-stakes): if sought, the case’s early stage determines whether the court addresses likelihood of success and irreparable harm.

Featured snippet answer: The controlling timeline elements are claim construction and any PTAB stay motions, because they affect whether the case results in an injunction, a consent judgment, or a delayed launch.

What motions and procedural milestones matter most in 1:23-cv-01332?

Executive summary: In AbbVie generic disputes, the docket’s most commercially significant events are (1) claim construction rulings, (2) summary judgment on invalidity/noninfringement, and (3) settlement-driven stipulated judgment timing.

Key procedural milestones

• Rule 16 scheduling and early disclosures
• Markman/claim construction order
• Daubert rulings on expert testimony
• Summary judgment motions
• Settlement conference orders
• Consent judgment or dismissal with prejudice
• Any interlocutory appeal after a permanent injunction or denial thereof

Featured snippet answer: The highest impact milestones are the first claim construction rulings and any summary judgment findings, because they define whether Hetero’s proposed product can “design around” and whether AbbVie’s asserted patents remain enforceable.

Has AbbVie v. Hetero reached claim construction or dispositive rulings?

Executive summary: Without the docket’s specific order entries and dates, a precise status call on claim construction, summary judgment, and trial scheduling cannot be accurately stated from the case number alone.

Featured snippet answer: The litigation posture must be tied to specific docket entries to confirm whether the court has ruled on claim construction or invalidity. The only business-usable way to assess launch timing is to map AbbVie’s asserted patents to the procedural stage that governs enforceability.

What is AbbVie’s patent estate strength against Hetero in this case?

Executive summary: In Hatch-Waxman-style disputes, the “strength” assessment is less about the raw number of patents and more about (1) whether claims are compositionally and analytically testable, (2) whether any claims have been previously litigated, (3) whether the asserted claims track regulatory-relevant product attributes, and (4) whether validity challenges have a plausible pathway (prior art coverage, enablement, written description).

How to evaluate enforceability leverage

• Asserted claim independence: Independent claims with tight structural definitions reduce design-around options.
• Enablement and written description: Weak disclosure can create invalidity risk.
• Obviousness exposure: Multiple art combinations can be decisive if the court is skeptical of secondary considerations.
• Existing adverse precedent: Prior invalidation rulings on similar patents in other districts lower enforcement value.

Featured snippet answer: Patent estate strength depends on claim construction outcomes and the ability to maintain infringement and validity positions through summary judgment.

Does Hetero’s entry face Paragraph IV risks in this case?

Executive summary: If Hetero challenged a listed patent under the Orange Book framework via a Paragraph IV certification (typical for generic suits), AbbVie’s infringement claims in 1:23-cv-01332 indicate the litigation is the mechanism that blocks entry until resolution or settlement.

Commercial risk mapping

• If the court upholds infringement: launch is typically enjoined or delayed via a permanent injunction and/or a stipulated judgment.
• If claims are found invalid or not infringed: Hetero can enter once regulatory exclusivity is cleared.
• If settlement occurs: an agreed launch date or modified label can take the dispute off the docket.

Featured snippet answer: Paragraph IV litigation risk is highest when asserted patents are close to the product attributes that drive approval and bioequivalence, and when Hetero cannot credibly alter the accused technical features.

What is the likely settlement and injunction scenario in AbbVie v. Hetero (1:23-cv-01332)?

Executive summary: Settlement in AbbVie generic cases usually resolves one of three commercial endpoints: (1) stipulated noninfringement without entry restrictions (rare for brand plaintiffs), (2) delayed entry with a negotiated “design around” or product labeling changes, or (3) an entry “launch at risk” scenario if the court declines to grant an injunction.

Settlement structure commonly seen

• Stipulated dismissal with prejudice
• Consent judgment with specific entry/date terms
• License or covenant not to sue terms (in some settlements)
• Ongoing royalties only if the parties negotiated a paid license structure (less common in pure Paragraph IV contexts)

Featured snippet answer: The most commercially likely outcomes are a negotiated delay tied to patent expiry and/or a consent judgment that fixes the launch date.

Orange Book status: which AbbVie listed patents are implicated?

Executive summary: The Orange Book patent list must be cross-referenced to determine which listed patents correspond to the asserted claims in 1:23-cv-01332. The case number alone does not provide the asserted patent numbers.

What to extract from the Orange Book for litigation mapping

• Listed active ingredient
• Listed dosage form/strength
• Patent number, expiration date
• Patent type: drug substance, drug product, method of use, etc.
• Regulatory exclusivity and patent linkage

Featured snippet answer: Litigation timing and generic launch risk are controlled by the latest-to-expire Orange Book patent(s) that match the asserted claims.

How does this case compare with other AbbVie vs. Hetero disputes?

Executive summary: Without docket-specific asserted patents and claims, a defensible comparison cannot be produced. Business users generally compare:

• Whether the same formulation/process patents are being asserted again across multiple defendants
• Whether claim construction patterns are repeating (indicating expected outcomes)
• Whether AbbVie’s strategy shifts toward method-of-use vs. composition claims

Featured snippet answer: The comparison requires the asserted patent set and outcomes in related AbbVie-Hetero cases to be accurate; the case number alone is insufficient.

Generic entry launch risks for Hetero: what could delay or accelerate entry?

Executive summary: Launch timing exposure is driven by (1) whether any asserted patents are found enforceable, (2) whether the court issues an injunction or the parties enter a consent judgment, and (3) whether regulatory exclusivities (including 180-day exclusivity for first filers, if applicable) constrain market entry.

Delay drivers

• Upheld infringement for a composition or method claim
• Scheduling delays that keep the court from a dispositive ruling before regulatory readiness
• PTAB stays (if tied to the same patents)

Acceleration drivers

• Early summary judgment of noninfringement or invalidity
• Settlement that permits earlier entry or “at risk” launch
• Narrow claim construction that excludes Hetero’s product

Featured snippet answer: Entry risk is highest when the accused product attributes track the strongest asserted claim limitations and when dispositive rulings are unlikely before the FDA approval readiness window.

Key commercial implications for AbbVie and Hetero

Executive summary: This dispute affects AbbVie’s ability to deter generic competition and protects revenues tied to the brand. For Hetero, the outcome sets either a fixed delayed-entry date through settlement or a viable launch path after invalidity/noninfringement.

Revenue and market share exposure channels

• Loss of exclusivity value if patents fall
• Incremental margin sensitivity if Hetero enters with competitive pricing
• Brand switching risk depending on therapeutic category substitution patterns

Featured snippet answer: The case’s economic impact equals the probability of an enforceable injunction and the time value of exclusivity protection versus expected generic launch.

Key Takeaways

• 1:23-cv-01332 is an AbbVie patent infringement dispute against Hetero USA, Inc. tied to an FDA-linked generic market entry.
• The commercially decisive variables are asserted patent scope, claim construction outcomes, and whether settlement leads to a stipulated entry delay or consent judgment.
• Launch risk for Hetero hinges on whether AbbVie retains enforceable claims through dispositive motion practice and whether any Orange Book listed patents implicated by the suit remain unblocked.

FAQs

1. How do claim construction rulings typically affect generic noninfringement arguments in AbbVie-style Hatch-Waxman cases?
2. What settlement terms most often control market entry dates in brand vs. generic disputes involving AbbVie and Hetero?
3. Which patent types (drug substance, drug product, method of use) most commonly survive validity challenges in this litigation class?
4. How do PTAB stays influence district court schedules and launch timing in Paragraph IV disputes?
5. What Orange Book patent expiry drives the last possible generic entry date when multiple patents are asserted?

References

1. United States District Court docket, AbbVie Inc. v. Hetero USA, Inc., No. 1:23-cv-01332 (case filings and docket entries).